Controversies in the Management of Viral Hepatitis (C-Hep)

Dear Friends and Colleagues,

Following the success of the 1st World Congress on Controversies in the Management of Viral Hepatitis (C-Hep), we are very pleased to invite you to participate in the 2nd C-Hep Congress which will be held in Berlin, Germany on October 18-20, 2012.

The large attendance and enthusiastic feedback of the 1st Congress held last May in Barcelona highlighted the need for such a meeting focusing on the needs of the busy clinician caring for HCV and HBV infected patients. The C-Hep Congress attempts to summarize all the key new data recently presented – and how it might be implemented in routine care of Hepatitis B and C patients. Overviews, state of the art lectures and controversial debates with the outstanding faculty of prominent world leaders presenting both pro and con positions challenge and explore the optimal treatment for patients, including the appropriate use of new drugs. This educational Congress focuses on clinical practices in Viral Hepatitis and benefits not only Hepatologists and Infectious Diseases specialist, but also general practitioners, internists and primary care physicians with a desire to gain knowledge in these exciting advances.

The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment.

We look forward to welcoming you at the 2nd C-Hep Congress in the lovely city of Berlin.
+ show speakers and program
14:00-16:00
PLENARY SESSION 1
HALL A

Moderators: Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel
14:00-14:05
Chairpersons Congress Welcome Address
14:05-14:30
HCV in 2020: Any cases left? Rafael Esteban, Spain
14:30-14:35
Discussion
14:35-15:00
HCV vaccine: Where do we stand? Ulrich Spengler , Germany
15:00-15:05
Discussion
Interferon-free HCV therapy: Are we getting there?
15:05-15:25
No: Graham Foster, UK
15:25-15:45
Yes: Heiner Wedemeyer, Germany
15:45-16:00
Discussion

16:00-17:30
Pipeline Showcase: New Drugs on the Horizon

17:30-18:00
Coffee Break and Poster Exhibition

18:00-19:15
Janssen Satellite Symposium

19:15-20:30
Welcome Reception and Poster Prize Ceremony


Friday, October 19, 2012

09:00-11:00
PLENARY SESSION 2
HALL A

Moderators: Stefan Zeuzem, Germany & Eckart Schott, Germany
09:00-09:05
Overview of HCV sessions by HCV Program Director
Stefan Zeuzem , Germany
Direct Antivirals: How have the treatment paradigms changed?
09:05-09:10
Moderators Introduction
HCV Direct Acting Antivirals:
09:10-09:30
In treatment naïve: Stanislas Pol, France
09:30-09:50
In treatment experienced: Thomas Berg, Germany
09:50-10:10
Toxicity management: Christoph Hezode, Paris
10:10-10:40
Drug-drug interactions: David Back, UK
10:40-11:00
Panel discussion

11:00-11:30
Coffee Break

11:30-12:15
SESSION 3: Do we need to know genetic factors such as IL28B for treatment decision making?
HALL A

11:30-11:45
Yes: Vincent Soriano, Spain
11:45-12:00
No: Mathew Albert, France
12:00-12:15
Discussion

11:30-12:15
SESSION 4: HCV therapy is for specialists only?
HALL B

11:30-11:45
Yes: Marion Peters, USA
11:45-12:00
No: Michael Biermer, Germany
12:00-12:15
Discussion

12:15-13:00
Lunch Break

13:00-14:15
Merck Sharp & Dohme Satellite Symposium
Successful HCV Treatment in the Real World: Lessons From Clinical Practice
13:00-13:05
Welcome and Opening Remarks: Jürgen Rockstroh, Germany
13:05-13:20
Emerging Evidence Guiding Clinical Practice: Christoph Sarrazin, Germany
13:20-13:40
Managing Adverse Events in the Clinical Setting: Jean Michel Pawlotsky, France
13:40-14:00
Protease Inhibitors in Practice:Case Studies: Geoffrey Dusheiko, UK
14:00-14:10
Panel Discussion
14:10-14:15
Closing Remarks: Jürgen Rockstroh, Germany

14:15-15:00
SESSION 5: Patients should wait for DAA combination therapy
HALL A

14:15-14:30
Yes: Patrick Ingiliz, Germany
14:30-14:45
No: Geoffrey Dusheiko, UK
14:45-15:00
Discussion

14:15-15:00
SESSION 6: Resistance to HCV Protease Inhibitors: Game over?
HALL B

14:15-14:30
Yes: Jean Michel Pawlotsky , France
14:30-14:45
No: Christoph Sarrazin, Germany
14:45-15:00
Discussion

15:00-15:30
SESSION 7: Interactive Case Session
HALL A

How to treat HCV relapse after OLTX
Raffaele Bruno, Italy

15:00-15:30
SESSION 8: Interactive Case Session
Supported by an unrestricted grant from Boehringer Ingelheim
HALL B

How to treat HCV in HIV coinfection
Stefan Mauss, Germany

15:30-16:00
Coffee Break

16:00-17:30
PLENARY SESSION 9
HALL A

16:00-16:20
Fatty liver disease: what do we know?
Claus Niederau, Germany
16:20-16:40
Vitamin D and liver disease: Which role does it play?
Christian M. Lange, Germany
16:40-17:00
End-stage liver disease: What is new?
Marion Peters, USA
17:00-17:20
Treatment of HCC: state of the Art:
Massimo Puoti, Italy
17:20-17:30
Panel Discussion

Saturday, October 20, 2012

08:30-10:30
PLENARY SESSION 10: HBV THERAPY IN 2012
HALL A

Moderators: Fabien Zoulim, France & Jörg Petersen, Germany
08:30-08:35
Overview of HBV sessions by HBV Program Director: Fabien Zoulim, France
08:35-09:00
Hepatitis B Therapy: State of the Art and open challenges: Jörg Petersen, Germany
Is there a need for combination therapy?
09:00-09:15
Yes: Florian van Boemmel, Germany
09:15-09:30
No: Maria Buti, Spain
09:30-09:50
HBV preventive and therapeutic vaccines: What is new? Marie-Louise Michel, France
09:50-10:10 Hepatitis Delta: What is new? Heiner Wedemeyer, Germany
10:10-10:30
Panel Discussion

10:30-11:00
Coffee Break

11:00-11:45
PLENARY SESSION 11: Interactive Case Session
Supported by an unrestricted grant from Gilead Sciences Europe Ltd.
HALL A

Moderator: Fabien Zoulim , France
The challenging hepatitis B case
Mark Nelson, UK
Karine Lacombe, France

11:45-12:45
PLENARY SESSION 12
HALL A

11:45-12:00
Strategies to prevent HCC: What can we do? Mark Thursz, UK
12:00-12:15
Can we afford HCV DAAs for all? Maud Lemoine, France
12:15-12:45
What are the remaining challenges in hepatitis research? Michael Manns, Germany

18 Oct - 20 Oct 2012

Berlin
Germany
meeting website